Clinical Trials & Research
Oncology Nurse Navigators
High-Risk Cancer Genetics
See All Your Doctors in One Visit
Events & Support Groups
Fitness & Wellness
Home > Testing & Treatment > Clinical Trials & Research
Treatment options, finding physicians or seeking second opinions? Let us help you find the answers. Contact us.
Clinical trials are research studies that have been carefully designed to answer questions about new ways to prevent cancer, treat cancer, manage side effects of treatment, and improve quality of life.
The Hall-Perrine Cancer Center participates in national clinical trials through the National Cancer Institute (NCI) and national and international studies through the pharmaceutical industry. These types of clinical trials are leading to major breakthroughs in cancer treatment in our own community.
Through the Iowa-Wide Oncology Research Coalition (I-WORC), Oncology Associates at Mercy Medical Center actively participates in more than 40 clinical trials at any given time. This allows a great number of patients access to trials based on the cancer and stage of cancer.
For more information about clinical trials, contact:
Jeanne Noble, at (319) 363-2690 ext. 1 or email@example.com
Laurie Burke, at (319) 363-2690 ext. 2 or firstname.lastname@example.org
Rand Ph III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Br Ca Pts (CT1-3N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
A011502: Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Rand Ph III Trial of Adjuvant Therapy Comparing Doxorubicin + Cyclophosphamide Followed by Weekly Paclitaxel w/ or w/o Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502
S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
NRG-GI002:A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
S0820: Double-Blind Placebo-Controlled Trial of Eflornithine & Sulindac to Prevent Recurrence of High Risk Adenomas & Second Primary Colorectal Cancers in Pts w/ Stage 0-III Colon or Rectal Ca, Ph III- Preventing Adenomas of the Colon w/ Eflornithine & Sulindac (PACES)
A021502: Randomized Trial of Standard Chemotherapy Alone orCombined with Atezolizumab as Adjuvant Therapy for Patients with Stage IIIColon Cancer and Deficient DNA Mismatch Repair
WF-1806:Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
A021703: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: ARandomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
NRG-GU002 - PhaseII-III Trial of Adjuvant Radiotherapy and Androgen Deprivation FollowingRadical Prostatectomy with or Without Adjuvant Docetaxel
A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
WF-97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
The National Myelodysplastic Syndromes (MDS) Study
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST) **Screening trial for A081105 and E4512**
A081105: Rand, Double-Blind, Placebo-Controlled Study of Erlotinib or Placebo in Pts w/ Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC
A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO - **Must be enrolled on screening trial A151216**
Ph III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib Vs. Placebo for Pts w/ Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein **Must be enrolled on screening trial A151216**
EA5163: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with ImmunobiomarkerSIGNature-Driven Analysis
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
S1801:Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475(Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
EA6174: STAMP: SurgicallyTreated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NCI 10231: NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
S1714: Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients – This is for Breast, Ovarian and NSCLC cancers
A221602: OlanzapineWith or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nauseaand Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC):A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Please note: Participation in clinical trials require that participants meet very specific eligibility criteria. Please check with your physician to see if you may be eligible. This website is periodically updated to list studies currently available. Please speak with your doctor to inquire if a particular clinical trial is currently enrolling patients.
Clinical Trials Matching Service is a free, confidential program that helps patients, their families and healthcare professionals find cancer clinical trials most appropriate to a specific patient, taking their medical and personal history in consideration. For more information, call 1-800-303-5691 or visit http://cancer.org/clinicaltrials.
The National Cancer Institute (NCI) offers a clinical trials search feature along with patient education on clinical trials. For more information, go to http://www.cancer.gov/clinicaltrials.